MOBILITY trial showcases company’s leadership in developing innovative endovascular treatment options ABBOTT PARK, Ill., April 1 (HSMN NewsFeed) — Abbott (NYSE: ABT) today announced the initiation of MOBILITY, a clinical trial studying the safety and…
Devices, Interventional
Abbott, Absolute Pro, MOBILITY trial, PAD , Peripheral Stent

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “Abbott Initiates U.S. Study of Absolute Pro(TM) Peripheral Stent System for Iliac Artery Disease”
Leave a Comment